102 related articles for article (PubMed ID: 25478788)
1. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.
Lemurell M; Ulander J; Winiwarter S; Dahlén A; Davidsson Ö; Emtenäs H; Broddefalk J; Swanson M; Hovdal D; Plowright AT; Pettersen A; Rydén-Landergren M; Barlind J; Llinas A; Herslöf M; Drmota T; Sigfridsson K; Moses S; Whatling C
J Med Chem; 2015 Jan; 58(2):897-911. PubMed ID: 25478788
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of [(3) H] and [(2) H6 ]AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP).
Lindelöf Å; Ericsson C; Simonsson R; Nilsson G; Grönberg G; Elmore CS
J Labelled Comp Radiopharm; 2016 Jul; 59(9):340-5. PubMed ID: 27298225
[TBL] [Abstract][Full Text] [Related]
3. Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.
Lemurell M; Ulander J; Emtenäs H; Winiwarter S; Broddefalk J; Swanson M; Hayes MA; Prieto Garcia L; Westin Eriksson A; Meuller J; Cassel J; Saarinen G; Yuan ZQ; Löfberg C; Karlsson S; Sundqvist M; Whatling C
J Med Chem; 2019 May; 62(9):4325-4349. PubMed ID: 30929436
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT; Çalışkan B; Banoglu E
Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
[TBL] [Abstract][Full Text] [Related]
5. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
Stock NS; Bain G; Zunic J; Li Y; Ziff J; Roppe J; Santini A; Darlington J; Prodanovich P; King CD; Baccei C; Lee C; Rong H; Chapman C; Broadhead A; Lorrain D; Correa L; Hutchinson JH; Evans JF; Prasit P
J Med Chem; 2011 Dec; 54(23):8013-29. PubMed ID: 22059882
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of endo- and exo-aryl-substitutions and central scaffold modifications on diphenyl substituted alkanes as 5-lipoxygenase activating protein inhibitors.
Chu L; Armstrong HM; Chang LL; Cheng AF; Colwell L; Cui J; Evans J; Galka A; Goulet MT; Hayes N; Lo J; Menke J; Ok HO; Ondeyka DL; Patel M; Quaker GM; Sings H; Witkin SL; Zhao A; Ujjainwalla F
Bioorg Med Chem Lett; 2012 Jun; 22(12):4133-8. PubMed ID: 22578458
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
8. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Levent S; Gerstmeier J; Olgaç A; Nikels F; Garscha U; Carotti A; Macchiarulo A; Werz O; Banoglu E; Çalışkan B
Eur J Med Chem; 2016 Oct; 122():510-519. PubMed ID: 27423639
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).
Banoglu E; Çelikoğlu E; Völker S; Olgaç A; Gerstmeier J; Garscha U; Çalışkan B; Schubert US; Carotti A; Macchiarulo A; Werz O
Eur J Med Chem; 2016 May; 113():1-10. PubMed ID: 26922224
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).
Takahashi H; Riether D; Bartolozzi A; Bosanac T; Berger V; Binetti R; Broadwater J; Chen Z; Crux R; De Lombaert S; Dave R; Dines JA; Fadra-Khan T; Flegg A; Garrigou M; Hao MH; Huber J; Hutzler JM; Kerr S; Kotey A; Liu W; Lo HY; Loke PL; Mahaney PE; Morwick TM; Napier S; Olague A; Pack E; Padyana AK; Thomson DS; Tye H; Wu L; Zindell RM; Abeywardane A; Simpson T
J Med Chem; 2015 Feb; 58(4):1669-90. PubMed ID: 25671290
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Pettersen D; Broddefalk J; Emtenäs H; Hayes MA; Lemurell M; Swanson M; Ulander J; Whatling C; Amilon C; Ericsson H; Westin Eriksson A; Granberg K; Plowright AT; Shamovsky I; Dellsèn A; Sundqvist M; Någård M; Lindstedt EL
J Med Chem; 2019 May; 62(9):4312-4324. PubMed ID: 30869888
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
[TBL] [Abstract][Full Text] [Related]
16. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
[TBL] [Abstract][Full Text] [Related]
17. Research on heterocyclic compounds. X.-Imidazo[1,2-a]pyrazine derivatives: synthesis and antiinflammatory activity.
Abignente E; Arena F; De Caprariis P; Nuzzetti R; Marmo E; Lampa E; Rosatti E; Ottavo R
Farmaco Sci; 1981 Jan; 36(1):61-80. PubMed ID: 6970683
[TBL] [Abstract][Full Text] [Related]
18. Recent advances for FLAP inhibitors.
Pettersen D; Davidsson Ö; Whatling C
Bioorg Med Chem Lett; 2015 Jul; 25(13):2607-12. PubMed ID: 26004579
[TBL] [Abstract][Full Text] [Related]
19. First asymmetric synthesis of CJ-14877 and its enantiomer and their interleukin-1beta inhibitory activities.
Aoyagi Y; Adachi Y; Akagi S; Ohno N; Takeya K
Bioorg Med Chem Lett; 2009 Apr; 19(7):1876-8. PubMed ID: 19272778
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
